Zelluna ASA

ZLNA · Oslo Børs · Healthcare

19.70NOK −3.4%last day

Price as of 2 October 2026

The price over the past year, with dividends: +64.3%

Performance

1 month

−18.6%

1 year

+64.3%

3 years, per year

−70.9%

5 years, per year

−57.0%

Largest fall, 3 years

−99.5%

Below the peak now

−98.8%

Volatility, 1 year

72.5%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

5.6

Dividend yield

0.0%

Return on equity

−114.8%

Net margin

–

Market value

60 m USD

Quality, value and trend

Where Zelluna stands against every Nordic stock today. 100 is best.

Quality96

Profitability and a sound balance sheet over time. Better than 96% of Nordic stocks.

Value2

The price measured against earnings, assets and cash flow. Better than 2% of Nordic stocks.

Trend82

The price development over the past year. Better than 82% of Nordic stocks.

Combined67

Quality, value and trend together. Better than 67% of Nordic stocks.

About Zelluna

Zelluna ASA is a company in healthcare, listed on Oslo Børs. The share trades in NOK. It has around 15 employees.

Zelluna ASA, a clinical-stage biotechnology company, engages in the development of T-cell receptor guided natural killer cell therapies in Norway. It develops ZI-MA4-1 which is in Phase I clinical trial for the treatment of non-small cell lung cancer, ovarian, and head and neck synovial sarcoma; ZI-KL1-1 which is in preclinical trial for the treatment of breast, gastric, lung, pancreatic, and cervix cancers; and ZI-PR-1 which is in discovery stage for the treatment of solid tumors. The company was incorporated in 2016 and is headquartered in Oslo, Norway.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis